OneAscent Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History

OneAscent Wealth Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-664	Closed	-$278K	–	173
2024 Q1	$278K	Sell	664 -7	-1%	-$2.96K	0.11%	137
2023 Q4	$273K	Sell	671 -479	-42%	-$177K	0.11%	132
2023 Q3	$400K	Buy	1,150 +34	+3%	+$11.9K	0.18%	79
2023 Q2	$393K	Buy	1,116 +1	+0.1%	+$337	0.19%	49
2023 Q1	$351K	Sell	1,115 -170	-13%	-$51K	0.14%	100
2022 Q4	$371K	Sell	1,285 -53	-4%	-$16.2K	0.17%	78
2022 Q3	$387K	Buy	1,338 +16	+1%	+$4.6K	0.2%	61
2022 Q2	$373K	Buy	1,322 +77	+6%	+$20.6K	0.19%	85
2022 Q1	$325K	Buy	+1,245	New	+$295K	0.16%	130
2021 Q1	–	Sell	-2,298	Closed	-$543K	–	236
2020 Q4	$543K	Buy	+2,298	New	+$527K	0.25%	96

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

OneAscent Wealth Management's VRTX Position: Q2 2024 in Review

OneAscent Wealth Management sold out of Vertex Pharmaceuticals (VRTX) in Q2 2024, closing a stake of 664 shares — an estimated $278K sold.

OneAscent Wealth Management first reported a position in VRTX in Q4 2020 and held it in 10 quarters. The position peaked at $543K in Q4 2020. 1,546 funds tracked by Wall St. Rank hold VRTX as of Q2 2024.

OneAscent Wealth Management reported no remaining Vertex Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
OneAscent Wealth Management sold 664 Vertex Pharmaceuticals shares in Q2 2024, an estimated $278K.
OneAscent Wealth Management first reported a position in Vertex Pharmaceuticals in Q4 2020 and held it in 10 quarters.
OneAscent Wealth Management's Vertex Pharmaceuticals position peaked at $543K in Q4 2020.
1,546 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2024.

Based on OneAscent Wealth Management's 13F filing for Q2 2024, filed 17 Jul 2024.